Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 25, 2024

https://www.globenewswire.com/news-release/2024/05/25/2888237/0/en/Vera-Therapeutics-Presents-72-week-eGFR-Stabilization-and-Rapid-Hematuria-Improvement-in-Phase-2b-ORIGIN-Study-of-Atacicept-in-IgAN-at-the-61st-European-Renal-Association-Congress.html

BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.